CTLA4 and melanoma: Similarly, the analysis of another cohort from Cancer-Immu algorithm50,51 suggested that CHAC1 expression was also elevated in melanoma patients who responded to CTLA-4 blockade therapy (Supplementary Fig. 7b), and patients with higher CHAC1 expression had increased overall survival or progression-free survival (Supplementary Fig. 7c).